Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
$656K Sell
16,075
-571
-3% -$24.7K 0.18% 92
2022
Q4
$853K Sell
16,646
-13
-0.1% -$623 0.24% 81
2022
Q3
$729K Sell
16,659
-576
-3% -$28K 0.21% 82
2022
Q2
$904K Sell
17,235
-94
-0.5% -$4.79K 0.25% 84
2022
Q1
$897K Sell
17,329
-892
-5% -$46.3K 0.21% 88
2021
Q4
$1.08M Buy
18,221
+1,948
+12% +$96.5K 0.24% 89
2021
Q3
$700K Sell
16,273
-1,150
-7% -$50.9K 0.18% 100
2021
Q2
$682K Sell
17,423
-300
-2% -$11.7K 0.18% 101
2021
Q1
$642K Buy
17,723
+646
+4% +$22.9K 0.19% 98
2020
Q4
$629K Sell
17,077
-513
-3% -$18.8K 0.21% 90
2020
Q3
$607K Buy
17,590
+290
+2% +$10.2K 0.22% 83
2020
Q2
$566K Sell
17,300
-111,432
-87% -$3.79M 0.23% 82
2020
Q1
$4.35M Buy
128,732
+112,343
+685% +$3.83M 0.65% 34
2019
Q4
$614K Sell
16,389
-5,349
-25% -$191K 0.26% 70
2019
Q3
$731K Sell
21,738
-1,021
-4% -$37.1K 0.4% 53
2019
Q2
$935K Buy
22,759
+2
+0% +$79 0.55% 44
2019
Q1
$917K Sell
22,757
-3,419
-13% -$137K 0.57% 45
2018
Q4
$1.08M Buy
+26,176
New +$1.09M 0.73% 35

Other funds holding PFE

HNP Capital's PFE Position: Q1 2023 in Review

HNP Capital reduced its Pfizer (PFE) stake by 3.4% in Q1 2023, selling an estimated $24.7K and leaving 16,075 shares worth $656K. The position accounts for 0.18% of the portfolio, ranked #92.

HNP Capital first reported a position in PFE in Q4 2018 and has held it in 18 quarters since. The position peaked at $4.35M in Q1 2020. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

  • HNP Capital held 16,075 shares of Pfizer worth $656K as of Q1 2023.
  • HNP Capital sold 571 Pfizer shares in Q1 2023, an estimated $24.7K.
  • Pfizer made up 0.18% of HNP Capital's portfolio in Q1 2023, its #92 holding.
  • HNP Capital first reported a position in Pfizer in Q4 2018 and has held it in 18 quarters since.
  • HNP Capital's Pfizer position peaked at $4.35M in Q1 2020.
  • 3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on HNP Capital's 13F filing for Q1 2023, filed 18 May 2023.